A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
Status:
TERMINATED
Trial end date:
2024-02-08
Target enrollment:
Participant gender:
Summary
This study aims to investigate the effect of multiple doses of BI 1358894 on pharmacokinetics of ethinylestradiol (EE) and drospirenone (DRSP) (Yasmin®)
Phase:
PHASE1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
drospirenone and ethinyl estradiol combination TRPC inhibitor BI 1358894